ENTX
Entera Bio Ltd.
Overview
Entera Bio develops oral tablet formulations of peptides and proteins for chronic diseases where injection-based therapies currently dominate.
Entera Bio Ltd is a Healthcare company operating in Biotechnology with a $72.9M market cap.
ENTX beat consensus EPS by 0.5% in Q1 FY2026, reported May 7, 2026.
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q1 FY20262026-05-07EPS$-0.07 vs $-0.15+53.3%Rev$0 vs ——EODHD
- Q4 FY20252026-03-26EPS$-0.06 vs $-0.11+45.5%Rev$0 vs ——EODHD
- Q3 FY20252025-11-13EPS$0.07 vs $-0.09+100.0%Rev$0 vs ——EODHD
- Q2 FY20252025-08-07EPS$-0.06 vs $-0.11+45.5%Rev$0 vs ——EODHD
- Q1 FY20252025-05-07EPS$-0.06 vs $-0.07+13.3%Rev$42.0K vs ——EODHD
- Q4 FY20242025-03-05EPS$-0.06 vs $-0.08+25.0%Rev$82.0K vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.08 vs $-0.05-60.0%Rev$42.0K vs ——EODHD
- Q2 FY20242024-08-08EPS$-0.06 vs $-0.060.0%Rev$57.0K vs ——EODHD
- Q1 FY20242024-05-09EPS$-0.05 vs $-0.06+16.7%Rev$0 vs ——EODHD
- Q4 FY20232024-03-07EPS$-0.07 vs $-0.08+12.5%Rev$4.5M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.07 vs $-0.09+22.2%Rev$0 vs ——EODHD
- Q2 FY20232023-08-10EPS$-0.14 vs $-0.07-100.0%Rev$0 vs ——EODHD
- Q1 FY20232023-05-04EPS$-0.08 vs $-0.12+33.3%Rev$0 vs ——EODHD
- Q4 FY20222023-03-30EPS$-0.10 vs $-0.11+9.1%Rev$14.0K vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.11 vs $-0.13+15.4%Rev$8.0K vs ——EODHD
- Q2 FY20222022-08-10EPS$-0.11 vs $-0.16+31.3%Rev$44.0K vs ——EODHD
- Q1 FY20222022-05-11EPS$-0.13 vs $-0.18+27.8%Rev$68.0K vs ——EODHD
- Q4 FY20212022-03-07EPS$-0.21 vs $-0.23+8.7%Rev$165.0K vs ——EODHD
- Q3 FY20212021-11-09EPS$-0.09 vs $-0.11+18.2%Rev$140.0K vs ——EODHD
- Q2 FY20212021-08-15EPS$-0.21 vs $-0.12-75.0%Rev$109.0K vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-07 | $-0.07 | $-0.15 | +53.3% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-0.06 | $-0.11 | +45.5% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $0.07 | $-0.09 | +100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $-0.06 | $-0.11 | +45.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.06 | $-0.07 | +13.3% | $42.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-05 | $-0.06 | $-0.08 | +25.0% | $82.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.08 | $-0.05 | -60.0% | $42.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-0.06 | $-0.06 | 0.0% | $57.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-0.05 | $-0.06 | +16.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-07 | $-0.07 | $-0.08 | +12.5% | $4.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.07 | $-0.09 | +22.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-0.14 | $-0.07 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-04 | $-0.08 | $-0.12 | +33.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.10 | $-0.11 | +9.1% | $14.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.11 | $-0.13 | +15.4% | $8.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.11 | $-0.16 | +31.3% | $44.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.13 | $-0.18 | +27.8% | $68.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-07 | $-0.21 | $-0.23 | +8.7% | $165.0K | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.09 | $-0.11 | +18.2% | $140.0K | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.21 | $-0.12 | -75.0% | $109.0K | — | — | EODHD |
Source: EODHD. ENTX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ENTX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 6/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $0.79 | $0.77 | +2.4% | -2.3% | -2.3% |
| Q4 FY2022 | $0.61 | $0.63 | -3.7% | +0.8% | +1.4% |
| Q3 FY2022 | $0.90 | $0.84 | +7.7% | -4.4% | -6.2% |
| Q2 FY2022 | $0.78 | $0.74 | +5.7% | +1.7% | +1.9% |
| Q1 FY2021 | $0.70 | $0.71 | -1.7% | -0.2% | +1.6% |
| Q4 FY2021 | $0.73 | $0.75 | -2.8% | +2.6% | +0.6% |
| Q3 FY2021 | $1.00 | $0.91 | +10.4% | +4.0% | +3.1% |
| Q2 FY2021 | $0.95 | $0.97 | -2.4% | -0.3% | -1.2% |
| Q1 FY2020 | $0.81 | $0.74 | +9.7% | +5.6% | +4.7% |
| Q4 FY2020 | $0.92 | $0.83 | +10.7% | -4.3% | -4.6% |
Guidance change history
Sample- Q1 FY2022Maintained2022-04-15
- Q4 FY2022Maintained2022-13-15
- Q3 FY2022Raised2022-10-15
- Q2 FY2022Raised2022-07-15
- Q1 FY2021Maintained2021-04-15
- Q4 FY2021Maintained2021-13-15
- Q3 FY2021Raised2021-10-15
- Q2 FY2021Maintained2021-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Miranda Jayne ToledanoCEO1 yr 11 mono recorded callsCurrentSample
CEO since 2024 • 1/2 beats (50%) • last guidance raise Q1 FY2022
- Dana Yaacov-garbeliCFO2 yr 2 mono recorded callsCurrentSample
CFO since 2024 • 1/2 beats (50%) • last guidance cut Q3 FY2022
- Leslie Velka GautamChief Business Officer1 yr 1 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance cut Q2 FY2022
- Gregory BurshteinChief of R&D2 yr 1 mono recorded callsCurrentSample
OTHER since 2024 • 1/2 beats (50%) • last guidance raise Q2 FY2022
- Hillel GalitzerCOO0 mono recorded callsFormerSample
COO since 2025 • 1/2 beats (50%) • last guidance cut Q3 FY2022
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ENTX.
$ curl https://api.spokenalpha.com/v1/companies/ENTXFAQ
Frequently asked about ENTX
Where can I find Entera Bio Ltd.'s (ENTX) earnings call transcripts?
Spoken Alpha indexes ENTX's earnings call transcripts at https://spokenalpha.com/companies/ENTX. Each call links to attributed speakers and parsed analyst Q&A. Entera Bio Ltd.'s own investor relations page is at https://investors.enterabio.com/.
When was Entera Bio Ltd.'s most recent earnings call?
Entera Bio Ltd. (ENTX) held its most recent earnings call on 2022-05-18, covering fiscal Q1 2022.
What sector is ENTX in?
Entera Bio Ltd. (ENTX) operates in the Healthcare sector (Biotechnology industry).